Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Verici Dx Plc (GB:VRCI)
LSE:VRCI
Verici Dx Plc (VRCI) Share Price & Analysis
1 Followers
VRCI Stock Chart & Stats
Day’s Range0p - 0p
52-Week Range5.50p - 13.00p
Previous Close6.5p
Volume445.49K
Average Volume (3M)308.91K
Market Cap
£15.77M
Enterprise Value8.32M
Total Cash (Recent Filing)$9.80M
Total Debt (Recent Filing)$156.00K
Price to Earnings (P/E)―
Beta2.09
Next Earnings
Apr 09, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.04
Shares Outstanding242,541,467
10 Day Avg. Volume160,475
30 Day Avg. Volume308,908
Standard Deviation0.14
R-Squared0.45
Alpha0.24
Financial Highlights & Ratios
Price to Book (P/B)4.45
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-2.20
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Verici Dx Plc News
PremiumCompany Announcements
Verici Dx Plc Reports Revenue Growth and Strategic Progress
PremiumCompany Announcements
Verici Dx Plc to Unveil Mid-Year Results and Updates
PremiumCompany Announcements
Verici Dx Achieves Key Collaboration MilestonePremiumCompany Announcements
Verici Dx Shareholders Approve AGM Resolutions
PremiumCompany Announcements
Verici Dx Completes Key Sample Transfer
PremiumCompany Announcements
Verici Dx Announces AGM and Annual Report
PremiumCompany Announcements
Verici Dx Unveils Educational Kidney Transplant Guide
PremiumCompany Announcements
Verici Dx Plc: Strategic Growth and Financial StrengthOptions Prices
Currently, No data available
---
Ownership Overview
0.67% Insiders
0.04% Mutual Funds
0.00% Other Institutional Investors
99.29% Public Companies and
Individual Investors
VRCI FAQ
What was Verici Dx Plc’s price range in the past 12 months?
Verici Dx Plc lowest share price was 5.50p and its highest was 13.00p in the past 12 months.
What is Verici Dx Plc’s market cap?
Currently, no data Available
When is Verici Dx Plc’s upcoming earnings report date?
Verici Dx Plc’s upcoming earnings report date is Apr 09, 2025 which is in 256 days.
How were Verici Dx Plc’s earnings last quarter?
Verici Dx Plc released its earnings results on Jul 15, 2024. The company reported -0.005p earnings per share for the quarter, missing the consensus estimate of N/A by -0.005p.
Is Verici Dx Plc overvalued?
According to Wall Street analysts Verici Dx Plc’s price is currently Overvalued.
Does Verici Dx Plc pay dividends?
Verici Dx Plc does not currently pay dividends.
What is Verici Dx Plc’s EPS estimate?
Verici Dx Plc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Verici Dx Plc have?
Verici Dx Plc has 242,541,470 shares outstanding.
What happened to Verici Dx Plc’s price movement after its last earnings report?
Verici Dx Plc reported an EPS of -0.005p in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -4.321%.
Which hedge fund is a major shareholder of Verici Dx Plc?
Currently, no hedge funds are holding shares in GB:VRCI
---
Verici Dx Plc Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-46.93%
12-Months-Change
Fundamentals
Return on Equity
-113.90%
Trailing 12-Months
Asset Growth
-50.90%
Trailing 12-Months
Company Description
Verici Dx Plc
Verici Dx PLC is an immuno-diagnostics development company. The company is focused on developing diagnostics technologies which will help understand the outcomes of an organ transplant surgery. There are two products for clinical validation and commercialisation: Clarava, which is a pre-transplant prognosis for the risk of early acute rejection ("EAR"); and Tuteva, a post-transplant diagnostic focused upon acute cellular rejection including sub-clinical rejection not being diagnosed through the current standard of care of rising serum creatine levels.
---
Technical Analysis
---